Michael R. McDonnell
CIK: 0001121897
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jul 8, 2026MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
5.7K shares- - Jul 8, 2026MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
1.6K shares- - Jul 8, 2026MRNA
Moderna, Inc.
Award(A)DirectStock Option (Right to Buy)
7.4K shares- - May 18, 2026MMSI
MERIT MEDICAL SYSTEMS INC
Award(A)Direct3.5K shares- - May 5, 2026BAX
BAXTER INTERNATIONAL INC
Award(A)Direct12.8K shares- - Feb 13, 2026BAX
BAXTER INTERNATIONAL INC
Award(A)Direct1.8K shares- - Jun 2, 2025MMSI
MERIT MEDICAL SYSTEMS INC
Sale(S)Direct1.8K shares at avg. $94.51$165K - May 30, 2025MMSI
MERIT MEDICAL SYSTEMS INC
Sale(S)Direct1.8K shares at avg. $94.30$165K - May 15, 2025MMSI
MERIT MEDICAL SYSTEMS INC
Award(A)Direct2.2K shares- - Feb 10, 2025BIIB
BIOGEN INC.
Tax Payment(F)Direct1.4K shares at avg. $142.54$195K - Feb 10, 2025BIIB
BIOGEN INC.
Exercise(M)Direct3.3K shares- - Feb 7, 2025BIIB
BIOGEN INC.
Tax Payment(F)Direct786 shares at avg. $141.35$111K - Feb 7, 2025BIIB
BIOGEN INC.
Tax Payment(F)Direct716 shares at avg. $141.35$101K - Feb 7, 2025BIIB
BIOGEN INC.
Exercise(M)Direct2.2K shares- - Feb 7, 2025BIIB
BIOGEN INC.
Exercise(M)Direct2.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 8, 2026 |  MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 5,733 | - | - | Direct |
| Jul 8, 2026 | MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 1,618 | - | - | Direct |
| Jul 8, 2026 | MRNA Moderna, Inc. | Award(A) Stock Option (Right to Buy) | 7,415 | - | - | Direct |
| May 18, 2026 |  MMSI MERIT MEDICAL SYSTEMS INC | Award(A) | 3,457 | - | $0 | Direct |
| May 5, 2026 |  BAX BAXTER INTERNATIONAL INC | Award(A) | 12,836 | - | $0 | Direct |
| Feb 13, 2026 | BAX BAXTER INTERNATIONAL INC | Award(A) | 1,811 | - | $0 | Direct |
| Jun 2, 2025 | MMSI MERIT MEDICAL SYSTEMS INC | Sale(S) | 1,750 | $94.51 | $165,393 | Direct |
| May 30, 2025 | MMSI MERIT MEDICAL SYSTEMS INC | Sale(S) | 1,750 | $94.30 | $165,025 | Direct |
| May 15, 2025 | MMSI MERIT MEDICAL SYSTEMS INC | Award(A) | 2,152 | - | - | Direct |
| Feb 10, 2025 |  BIIB BIOGEN INC. | Tax Payment(F) | 1,371 | $142.54 | $195,422 | Direct |
| Feb 10, 2025 | BIIB BIOGEN INC. | Exercise(M) | 3,257 | - | - | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Tax Payment(F) | 786 | $141.35 | $111,101 | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Tax Payment(F) | 716 | $141.35 | $101,207 | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Exercise(M) | 2,216 | - | - | Direct |
| Feb 7, 2025 | BIIB BIOGEN INC. | Exercise(M) | 2,335 | - | - | Direct |
1-15 of 15 transactions
About McDonnell Michael R.
McDonnell Michael R. (SEC CIK 0001121897) files insider reports with the SEC as Director of Moderna, Inc. (MRNA), Director of MERIT MEDICAL SYSTEMS INC (MMSI) and Director of BAXTER INTERNATIONAL INC (BAX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by McDonnell Michael R. (2 Form 3, 8 Form 4), filed between Feb 10, 2025 and Jul 10, 2026. Those filings report 15 transactions, from Feb 7, 2025 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on McDonnell Michael R.'s filings is in CAMBRIDGE, MA.
Recent filings by McDonnell Michael R.
- Jul 8, 2026: Grants or awards of MRNA derivative securities (3 lines, Form 4, code A).
- May 18, 2026: Grant or award of MMSI shares (Form 4, code A).
- May 5, 2026: Grant or award of BAX shares (Form 4, code A).
- Feb 13, 2026: Grant or award of BAX shares (Form 4, code A).
- Jun 2, 2025: Open-market sale of MMSI shares (Form 4, code S).
Other insiders filing for Moderna, Inc. (MRNA)
- Hoge Stephen, President
- Mock James M, Chief Financial Officer
- Andres Juan, Chief Operating Officer
- Klinger Shannon Thyme, Chief Legal Officer
- Bancel Stephane, Chief Executive Officer
- Banque Soria Ester, Chief Commercial Officer